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Treatment of intact human platelets with the tumour-promoting phorbol ester, phorbol 12-myristate 13- 
acetate (PMA), specifically inhibited PGD2-induced cyclic AMP formation without affecting the regulation 
of cyclic AMP metabolism by PGL z, PGE 1, 6-keto-PGEl, adenosine or adrenaline. This action of PMA was: 
(i) concentration-dependent; (ii) not mediated by evoked formation or release of endogenous regulators of 
adenylate cyclase activity (thromboxane A 2or ADP); (iii) mimicked by 1,2-dioctanoylglycerol (DiCs) but 
not by 4~t-phorbol 12,13-didecanoate (which does not activate protein kinase C); (iv) attenuated by Stau- 
rosporine. These results indicate that activation of protein kinase C in platelets may provide a regulatory 
mechanism to abrogate the effects of the endogenous adenylate cyclase stimulant PGD 2 without compromis- 
ing the effects of exogenous stimulants of adenylate cyclase (PGI 2, 6-keto-PGE1, adenosine). 
Platelet; cyclic AMP; Protein kinase C 
1. INTRODUCTION 
Platelet reactivity is controlled by the complex 
interactions of at least two different intracellular 
second messenger systems. Inhibition of platelet 
responsiveness is mediated by agonist (e.g. PGI2, 
PGD2 or adenosine)-induced levation of in- 
tracellular cyclic AMP concentration [1]. Platelet 
activation in response to many agonists (e.g. 
thrombin, vasopressin, platelet-activating factor 
and thromboxane (TXA2)) is mediated via eleva- 
tion of cytosolic free Ca 2+ concentration ([Ca2+]i) 
and formation of 1,2-diacylglycerol (DG) [2,3]: 
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both events are possible sequelae of agonist- 
induced phosphoinositide hydrolysis [4]. There is 
much evidence that other agonists (e.g. adrenaline, 
ADP) that induce platelet activation inhibit 
adenylate cyclase in platelet lysates, an effect 
which, in intact platelets, is manifest as inhibition 
of agonist-induced cyclic AMP formation [1]. 
However, a cause and effect relationship between 
inhibition of adenylate cyclase and promotion of 
platelet activation remains to be established. Many 
of the effects of these intracellular messengers are 
mediated via activation of specific protein kinase 
enzymes; calcium/calmodulin-dependent pro ein 
kinases; DG-dependent protein kinase C and cyclic 
AMP-dependent protein kinase [4]. 
Besides its role in promoting platelet activation, 
a number of recent studies have indicated that ac- 
tivated protein kinase C may also subserve a 
negative feedback role to reverse or inhibit agonist- 
induced phosphoinositide hydrolysis and elevation 
of [Ca2+]i n platelets [5] and other cell types [6]. 
Moreover, in other cells, activation of protein 
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kinase C by tumour-promoting phorbol esters uch 
as phorbol 12-myristate 13-acetate (PMA) also 
modulates cellular cyclic AMP metabolism. In- 
deed, phorbol esters have been reported either to 
enhance basal or hormone-elevated cyclic AMP 
levels [7] or to inhibit agonist-induced levations in 
the cellular cyclic AMP content [8]. 
These actions of protein kinase C may be 
mediated by effects on the hormone receptor [9]; 
the guanine nucleotide-binding regulatory pro- 
teins, Ns/G~ [10] or Ni/Gi [11,12]; the catalytic 
subunit of adenylate cyclase [13] and/or cyclic 
nucleotide phosphodiesterase [14]. Moreover, pro- 
tein kinase C may mediate complex regulation of 
cyclic AMP metabolism by acting at different sites 
within a single cell type [15]. Here, we have in- 
vestigated the effects of protein kinase C activation 
on regulation of cyclic AMP metabolism in intact 
human platelets by agonists that act upon distinct 
receptors which are coupled via Ns (e.g. PGD2, 
PGI2, adenosine) or Ni (e.g. oe2-adrenoreceptors), 
respectively, to stimulation or inhibition of 
adenylate cyclase. 
2. EXPERIMENTAL 
Blood was obtained and plasma-free platelet 
suspensions (2 x 108 platelets per ml) were 
prepared by gel filtration as described [16]. Cyclic 
AMP was extracted from platelets using ethanol. 
The extracts were evaporated to dryness (60°C), 
reconstituted in acetate buffer (50 mM, pH 5) and 
the cyclic AMP content was estimated by radioim- 
munoassay using iodinated tracers [16]. 
Adenosine 3' ,5'-cyclic phosphoric acid 2 ' -0 -  
succinyl-3'-[125I]iodotyrosine methyl ester (600 Ci 
per mmol) was obtained from Amersham Interna- 
tional (Amersham, England). PGD2, PGI2, PGE~ 
and 6-keto-PGE~ were obtained from Upjohn 
(Kalamazoo, MI). 1,2-Dioctanoylglycerol (DiCs) 
was obtained from Avanti Polar Lipids (Birm- 
ingham, AL) and was dissolved in ethanol. Other 
reagents were obtained from Sigma (England); 
PMA and 4a,-phorbol 12,13-didecanoate (4a- 
PDD) were dissolved in DMSO and other reagents 
were dissolved in iso-osmotic saline. All incuba- 
tions (37°C) were performed in triplicate and ex- 
periments were repeated at least three times using 
blood obtained from different donors. 
3. RESULTS AND DISCUSSION 
Incubation (4 rain, 37°C) with PMA (~< 300 nM) 
did not alter the level of cyclic AMP in control 
(7.9 + 0.3 pmol/108 platelets) or isobutylmethyl- 
xanthine (IBMX; 1 mM, 30-60 min)-treated 
platelets (19.9 _+ 2.3 pmol/10 s platelets). Incuba- 
tion (2 min, 37°C) with PGD2 (63/~M), PGI2 
(~< 300 nM), PGE1 (~< 10/~M), 6-keto-PGEl 
(~<I0/~M) or adenosine (~<100/zM) resulted in 
concentration-dependent levations in platelet 
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Fig. I. Effects of PMA on agonist-induced levations in 
platelet cyclic AMP content. Gel-filtered platelet 
samples (0.4 ml, 2 x l0 s platelets per ml) were incubated 
(2 min) with the concentrations of PMA indicated 
before addition of submaximal concentrations of PGD2 
(300 nM) (o); PGEI (l/zM) (A); 6-keto-PGEl (1/zM) 
(m); PGI2 (100 nM) (o) or adenosine (10/,M) (A) for a 
further 2 min. Cyclic AMP content was estimated as 
described insection 2. The basal cyclic AMP content was 
8 + 0.3 pmol per l0 s platelets (n = 12) and the control 
elevations (in the presence of 0.15°70 DMSO) were as 
follows: PGD2, 81 _+ 4, n = 7; PGEh 18 +_ 4.2, n = 3; 
6-keto-PGE~, 11.5 +_ 1.8, n = 3; PGI2, 120 _+ 9.2, n = 
3; adenosine, 5.3 _+ 0.4, n = 3 (all expressed as pmol per 
108 platelets above the basal evel). Data were compared 
to the DMSO control using Student's t-test: **P < 
0.001. 
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cyclic AMP content (not shown). Submaximal 
concentrations of each compound (inducing be- 
tween 40 and 60% of maximal elevation in platelet 
cyclic AMP content) were selected in order to ex- 
amine the effects of PMA on agonist-induced 
cyclic AMP formation. Preincubation (2 min) with 
PMA (3-300nM) resulted in concentration- 
dependent inhibition of the rise in platelet cyclic 
AMP content induced by submaximal concentra- 
tions of PGD2 (300 nM) but not by PGI2 
(100 nM), PGE1 (1/zM), 6-keto-PGE1 (1/zM) or 
adenosine (1/zM) (fig.l). The inhibitory effect of 
PMA on PGD2-induced cyclic AMP formation 
(/5o = 7.5 nM) was shared by 1,2-dioctanoylgly- 
cerol (/5o = 30/zM), but not by the non-tumour- 
promoting phorbol ester 4a-PDD. Moreover these 
effects of PMA and DiCs were suppressed by 
Staurosporine (100 nM), an agent that inhibits 
protein kinase C [17] and impairs PMA- and 
DiCs-induced phosphorylation of the 40 kDa pro- 
tein, the major substrate.for platelet protein kinase 
C (not shown). Collectively, these observations in- 
dicate that selective inhibition of PGD2-induced 
cAMP formation by PMA and DiCs is consistent 
with, and may be attributed to, the activation of 
protein kinase C. 
As PMA is known to induce platelet activation, 
degranulation and eicosanoid biosynthesis, we in- 
vestigated whether the effects of PMA on 
PGD2-induced cyclic AMP formation could be 
mediated by agents (e.g. ADP, TXA2) released by 
platelets and which have been reported to inhibit 
adenylate cyclase [1,5]. In the presence of flur- 
biprofen (10/~M), which maximally inhibits pro- 
stanoid (TXA2) biosynthesis, PMA inhibited 
PGD2-induced cyclic AMP formation (I50 = 10 _ 
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Fig.2. Effects of apyrase on the inhibition of PGD2-induced elevation of platelet cyclic AMP concentration by(A) PMA 
and (B) ADP. Control (e) and apyrase (10 U ADPase per ml; 10 min)-treated (A) platelet samples were incubated for 
2 min with (A) PMA or (B) ADP at the concentrations i dicated prior to the addition of PGD2 (300 nM) for a further 
2 min and cyclic AMP content was monitored as described in section 2. Data are means _+ SE from three different 
experiments. 
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1.5 nM), indicating that this effect is not mediated 
by endogenous TXA2. 
The role of PMA-induced ADP release in block- 
ing PGD2-induced cyclic AMP formation was in- 
vestigated by treating platelets with the ADP 
scavengers apyrase or creatine phosphate (2 mM) 
plus creatine phosphokinase (50 U/ml). Under 
conditions where the inhibition of PGD2-induced 
cyclic AMP formation by exogenously added ADP 
(1-10#M) was abolished, apyrase had no signifi- 
cant effect on the inhibition by PMA (150 = 11 nM, 
fig.2). Similarly, this effect of PMA was not 
altered by incubation (10-40 min) with creatine 
phosphate plus creatine phosphokinase (not 
shown). Thus, PMA-induced inhibition of the rise 
in cyclic AMP content cannot be attributed to for- 
mation or release of endogenous inhibitors of 
adenylate cyclase. 
Activation of cyclic nucleotide phosphodi- 
esterase by protein kinase C could contribute, at 
least in part, to the actions of PMA. Accordingly, 
the effects of PMA on PGD2-induced cyclic AMP 
formation were examined in the presence of the 
phosphodiesterase inhibitor IBMX. Incubation 
(15-60 min) with IBMX (1 mM) resulted in a 
doubling of the PGD2-induced rise in cyclic AMP 
content but only marginally inhibited the effect of 
PMA (fig.3). Hence, the effect of PMA is most 
likely due to inhibition of PGD2-induced cyclic 
AMP formation although augmentation of phos- 
phodiesterase activity may contribute. 
The specificity of this action of PMA suggests 
that it is mediated via protein kinase C-dependent 
phosphorylation f the PGD2 receptor rather than 
via an effect on the 'G-proteins' or the adenylate 
cyclase catalytic subunit. In agreement with this, 
Ashby et al. [18] reported that neither PMA nor 
the synthetic diglyceride oleoylacetylglycerol had 
any direct effect on PGI2- or forskolin-induced 
cyclic AMP formation. Such inhibitory receptor 
phosphorylations have been demonstrated uSing a 
number of different receptors and cell systems 
[19]. 
The potential physiological role of this 
phenomenon is questionable since there is no 
evidence that in intact platelets agents (such as 
thrombin, vasopressin or platelet-activating fac- 
tor) which activate protein kinase C, via 
diacylglycerol formation, have any effect on 
PGD2-induced cyclic AMP formation. However, 
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Fig.3. Effect of IBMX on the inhibition of 
PGD2-induced elevation in cyclic AMP content by 
PMA. Control (o) and IBMX (1 mM, 20-50 min)- 
treated platelets (z~) were incubated with PMA (2 min) 
at the concentrations i dicated before addition of PGD2 
(300 nM) for a further 2 min arid cyclic AMP content 
was monitored as described in section 2. The 
PGD2-induced rise in cyclic AMP content (control 115 _+ 
10 pmol per 10 a cells; n = 3) was approximately doubled 
in the presence of IBMX (222 _+ 12 pmol per 108 cells, 
n = 3). Data are means + SE from three different 
experiments. 
the possibility remains that, under certain patho- 
physiological conditions, activation of protein 
kinase C in platelets may act to abrogate the effects 
of the endogenous (i.e. platelet-derived) adenylate 
cyclase stimulant PGD2, without compromising 
the actions of naturally occurring exogenous 
stimulants of adenylate cyclase (e.g. PGI2, 6-keto- 
PGEt or adenosine). Indeed, it has been noted that 
platelets from patients with myeloproliferative 
disorders or acute thrombotic episodes show a 
specific loss of PGD2-mediated control of 
adenylate cyclase activity whilst retaining normal 
PGI2 and PGEI responsiveness [19]. The potential 
role of  protein kinase C in these disorders is wor- 
thy of investigation. 
The possible effects of protein kinase C on the 
inhibitory control of adenylate cyclase activity in 
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intact platelets were investigated by examining the 
effects of PMA on adrenaline-induced inhibition 
of platelet cyclic AMP formation. Platelet 
crz-adrenoreceptors a e coupled to inhibition of 
adenylate cyclase via the inhibitory G-protein Ni 
[ll. Addition of adrenaline (1-10/zM) to intact 
platelets resulted in concentration-dependent in- 
hibition of the rises in cyclic AMP content induced 
by PGIz (100 nM), PGE1 (1/zM) or PGD2 (1/zM) 
(not shown). The inhibitory effects of adrenaline 
(1-5/~M) on PGEl-induced elevations in cyclic 
AMP content were unaffected by pre-incubation 
with PMA (4 1/¢M) (rigA). 
Hence, in intact platelets, protein kinase C ac- 
tivation does not interfere with cr2-adrenoreceptor- 
dependent, Ni-mediated, inhibition of cyclic AMP 
formation. This observation contrasts with the 
reported blockade of Niomediated inhibition of 
adenylate cyclase activity in platelets and $49 lym- 
phoma cells [11,12]. Whilst the reasons for this 
discrepancy are unknown, it may be explained by 
different experimental conditions: Jakobs and co- 
workers [11,12] measured cyclase activity in 
platelet membrane preparations whilst the present 
study was conducted using intact platelets. Indeed, 
studies in other cell types have revealed ifferences 
in the regulation of adenylate cyclase in lysates as 
compared to whole ceils where there may be com- 
plex interactions between the different intracellular 
second messenger systems [20]. 
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Fig.4. Effects of PMA on the modulation of platelet cyclic AMP content by PGE~, PGD2 and adrenaline. Where 
indicated, gel-filtered platelet samples were incubated with DMSO (0.15%, 4 min), PMA (300 nM, 4 min), adrenaline 
(1-5/zM, 2 min), PGE~ (1/¢M, 1 rain) or PGD2 (1/~M, 1 min) and cyclic AMP content was monitored as described 
in section 2. Data are means + SE from a single experiment representative of three. 
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